Device Trial Radar · NCT04058665
Hemostatic Agent Use and Intraoperative Blood Loss in Lumbar Spine Surgery
Last checked: Nov 19, 2026Latest source record: Apr 14, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
300
Actual
Start
Jun 18, 2019
Primary completion
Mar 1, 2022
Study completion Mar 1, 2022
Sponsor
- Lead sponsor
- Johns Hopkins UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Baxter Healthcare Corporation
- First posted
- Aug 15, 2019
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
Summary
As written by the sponsor on the registry.
Perioperative variables that can be used to create a bundled approach quality improvement protocol to minimize blood loss in spine surgery will be evaluated using retrospective data collection and multivariate analysis of previously performed spinal surgeries at Johns Hopkins Hospital. In particular the investigators are interested in determining whether FloSeal® contributes towards increased control over perioperative bleeding compared to other hemostatic agents for potential inclusion in a future bundled approach.
Conditions
- Blood Loss
Interventions
FlosealDevice
Hemostatic agent
Primary outcomes
What the sponsor says the trial is designed to measure.
- Total blood lossTime frame: 1 week
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Johns Hopkins University School of Medicine
Baltimore, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.